© 2022 by Elsevier GmbH
Bitte nutzen Sie das untenstehende Formular um uns Kritik, Fragen oder Anregungen zukommen zu lassen.
Willkommen
Mehr InformationenBL15-9783437228780.10001-8
10.1016/BL15-9783437228780.10001-8
L15-9783437228780
###
Pilzinfektionen
Definition und Basisinformation
Symptomatik und klinisches Bild
Diagnostik und Differenzialdiagnose
Therapie
Autorenadresse
Leitlinien
L1.
Cornely OA, Bassetti M, Calandra T, et al.: European Society for Clinical Microbiology and Infectious Diseases (ESCMID) Diagnosis and Management Guideline 2012 of Invasive Candidiasis in Intensive Care Unit Patients. Clin Microbiol Infect 18 (S7) (2012) 19–37.
L2.
Ruhnke M, Bohme A, Buchheidt D, et al.: Diagnosis of invasive fungal infections in hematology and oncology – Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 82 Suppl 2 (2003) S141–148.
L3.
Ullmann AJ, Aguado JM, Arikan-Akdagli S, et al.: Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect 24 (2018) e1–38.
L4.
Cornely OA, Arikan-Akdagli S, Dannaoui E, et al.: ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect 20 (S3) (2014) 5–26.
Literatur
1.
Cornely OA, Maertens J, Bresnik M, et al.: Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 44(10) (2007) 1289–1297.
2.
Cornely OA, Maertens J, Winston DJ, et al.: Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356(4) (2007) 348–359.
3.
Cornely OA, Ullmann AJ, Karthaus M: Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood 101(9) (2003) 3365–3372.
4.
de Pauw B, Walsh TJ, Donnelly JP, et al.: Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/ Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46(12) (2008) 1813–1821.
5.
Greenberg RN, Mullane K, van Burik JA, et al.: Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 50(1) (2006) 126–133.
6.
Herbrecht R, Denning DW, Patterson TF, et al.: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347(6) (2002) 408–415.
7.
Kuse ER, Chetchotisakd P, da Cunha CA, et al.: Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369(9572) (2007) 1519–1527.
8.
Mora-Duarte J, Betts R, Rotstein C, et al.: Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347(25) (2002) 2020–2029.
9.
Nebiker CA, Lardinois D, Junker L, et al.: Lung Resection in Hematologic Patients with Pulmonary Invasive Fungal Disease. Chest 143(4) (2012) 988–995.
10.
Pagano L, Valentini CG, Fianchi L, et al.: The role of neutrophils in the development and outcome of zygomycosis in haematological patients. Clin Microbiol Infect 15 Suppl 5 (2009) 33–36.
11.
Paltauf A: Mycosis mucorina. Ein Beitrag zur Kenntniss der menschlichen Fadenpilzerkrankungen (sic!). Archiv für pathologische Anatomie 102(25) (1885) 543–564.
12.
Pappas PG, Rotstein CM, Betts RF, et al.: Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 45(7) (2007) 883–893.
13.
Pascual A, Calandra T, Bolay S, et al.: Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 46(2) (2008) 201–211.
14.
Reboli A, Rotstein C, Pappas P, et al.: Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 356 (2007) 2472–2482.
15.
Roden MM, Zaoutis TE, Buchanan WL, et al.: Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 41(5) (2005) 634–653.
16.
Rüping MJ, Vehreschild JJ, Cornely OA: Patients at high risk of invasive fungal infections: when and how to treat. Drugs 68(14) (2008) 1941–1962.
17.
Skiada A, Pagano L, Groll A, et al.: Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect 17(12) (2011) 1859–1867.
18.
Trick WE, Fridkin SK, Edwards JR, et al.: Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989–1999. Clin Infect Dis 35(5) (2002) 627–630.
19.
van Burik JA, Hare RS, Solomon HF, et al.: Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 42(7) (2006) e61–65.
20.
Virchow R: Beiträge zur Lehre von den beim Menschen vorkommenden pflanzlichen Parasiten. Archiv für pathologische Anatomie 9(4) (1856) 557–593.